For instance, treatment of BRAF-mutant melanomas with BRAF inhibitor, vemurafenib, or with MEK inhibitor, selumetinib, leads to microphthalmia-associated transcription factor (MITF) signalling and elevated expression of the mitochondrial master regulator, PGC-1α. This evidence concerns the gene MITF and melanoma.